Pre-made Etesevimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-196

Pre-Made Etesevimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bamlanivimab/etesevimab is a combination of two monoclonal antibodies, bamlanivimab and etesevimab, administered together via intravenous infusion as a treatment for COVID-19. Both types of antibody target the surface spike protein of SARS-CoV-2.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-196-1mg 1mg 3090
GMP-Bios-ab-196-10mg 10mg Inquiry
GMP-Bios-ab-196-100mg 100mg Inquiry
GMP-Bios-ab-196-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Etesevimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody
INN Name Etesevimab
TargetSARS-CoV-2 Spike RBD
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI Structure7c01:CD
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesEli Lilly and Company;Institute of Microbiology of the Chinese Academy of Sciences;Shanghai Junshi Biosciences
Conditions ApprovedCOVID-19
Conditions Activena
Conditions Discontinuedna
Development Techna